Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

RegulatoryapprovedTN-401Positive

AI Analysis

Summary

Tenaya Therapeutics received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for TN-401 to treat PKP2-associated arrhythmogenic right ventricular cardiomyopathy, supported by positive interim data from the RIDGE-1 Phase 1b/2 trial showing reduced arrhythmia burden.

Clinical Trial Data

Phase

1b/2

Primary Endpoint

Met

Outcome Details

Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation

Importance:7/10

Sentiment:

0.80

RMAT DesignationFDA RegulatoryGene TherapyCardiac DiseasePositive Data

Related Companies

$SHWZ

Read the original article

Published by GlobeNewswire Clinical Studies on September 14, 2026 12:30 PM

Read Original